Vaccine Breaking News

Vaccine breaking news brought to you by Precision Vaccinations.

Aug 6, 2022 • 4:11 am CDT
by Yair Ventura Filho

The West Virginia Department of Health and Human Resources confirmed reports people had developed influenza-like illness after working closely with swine (pigs) at the Jackson County Fair.

In addition, laboratory Services returned presumptive positive influenza A(H3N2) variant (A(H3N2)v) virus on at least one child specimen, reported to the U.S. CDC on August 5, 2022.

This is the first influenza A(H3N2)v virus identified in the USA in 2022.

The patient is a child < 18 years, was not hospitalized, and is recovering from their illness.

No person-to-person spread of this virus has been identified in this case.

“If experiencing symptoms such as fever, runny nose, sore throat, cough or congestion, it is extremely important to let your healthcare provider know if you or your loved one has visited a recent outdoor event with swine and to be appropriately evaluated,” said Dr. Ayne Amjad, in a media statement on August 3, 2022. 

“These symptoms usually show up 1-3 days after exposure.”

When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a Zoonontic “variant influenza virus.”

These infections are relatively rare but happen sporadically.

Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at

Furthermore, U.S. FDA-approved flu shots are not protective against swine influenza A(H3N2).

And information regarding Zoonotic influenza and the ongoing avian influenza (HAPI) outbreak in the USA are updated regularly.

Note: this news was manually curated for mobile readers.

Aug 5, 2022 • 12:20 pm CDT
from Pixabay

The U.S. Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR) announced today that more than​ 602,000​ ​doses of Bavarian Nordic’s Jynneos vaccine were available in the USA.

Jynneos is a U.S. FDA-licensed vaccine (2019) indicated for the prevention of smallpox and monkeypox.

As of August 3, 2022, deliveries from the U.S. Strategic National Stockpile to jurisdictions to support their local monkeypox vaccination response efforts had reached 580,733.

The SNS began shipping doses of Jynneos on May 21.

The majority of Jynneos distributions have been to California, New York, and Florida.

The good news is vaccine supplies will significantly increase in the months ahead.

On July 15, 2022, ASPR announced that it had ordered an additional 2.5 million doses of Jynneos vaccines.

This order will bring the federal government’s ​available supply to more than 6.9 million doses by mid-​2023. 

And to better update the general public, HHS previously announced an enhanced national strategy to vaccinate and protect at-risk individuals from monkeypox infections by prioritizing Jynneos for areas with the highest number of cases.

Furthermore, the U.S. government named leaders to execute its monkeypox outbreak initiatives on August 2.

Robert Fenton is now the White House National Monkeypox Response Coordinator, and Dr. Demetre Daskalakis is the White House National Monkeypox Response Deputy Coordinator.

Additional monkeypox vaccine news is posted at

Aug 5, 2022 • 8:26 am CDT
from Pixabay

Massachusetts-based Vaxess Technologies, Inc. recently announced that it had launched a phase 1 clinical trial for the H1 influenza vaccine delivered via Vaxess's MIMIX™ patch. The Company intends to report the initial finding in 4Q2022. 

Vaxess confirmed on August 3, 2022, it had enrolled 45 healthy adult volunteers ages 18-39 to evaluate the safety, reactogenicity, tolerability, and immunogenicity profiles for two influenza vaccine dose levels, fractional H1 vaccine dose level 7.5 μg and standard H1 vaccine dose level 15 μg vs. placebo.

Vaxess will also evaluate the durability of the immune response for each vaccine dose level and assess, in at least a subset of samples, the breadth of influenza A H1 antigen responses.

For the phase 1 trial, the H1 influenza vaccine is delivered by VX-103 (a MIMIX Array Patch System).

In the previous testing of Vaxess's influenza MIMIX Array Patch system on mice, the Company found enhanced humoral and cellular immune responses to the influenza vaccine when compared to receiving the vaccine via intramuscular injection.

"...getting a vaccine usually means receiving an injection via syringe and needle ... which is uncomfortable and time-consuming ... and requires extraordinary supply chain resources to distribute temperature-controlled vaccines to pharmacies, hospitals, and doctors' offices," said Lynda Tussey, chief development officer at Vaxess, in a press release.

"Vaxess's MIMIX patch will make distributing and administering vaccines easier."

"Soon, we'll live in a world where you can have a vaccine patch mailed right to your door, and put it on in the comfort of your home, whether for a seasonal vaccination or to address a future COVID-like pandemic." 

Vaxess's phase 1 trial builds on the Company's research published in September 2021, "Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles."

The study showed that sustained release immunization promotes strong and long-lasting anti-influenza antibody responses and enhanced protection against fatalities. 

Additional U.S. FDA-authorized influenza vaccine information for the 2022-2023 flu season is posted at

Note: Vaxess press release was manually curated for mobile readers. 

Aug 5, 2022 • 1:51 am CDT
by Gerd Altmann

The peer-review New England Journal of Medicine recently published a decision to require human trial data to show that SIGA Technologies' antiviral medication TPOXX is safe and effective in treating people infected with the monkeypox virus (MPXV).

This Perspective was presented on August 3, 2022, by Adam Sherwat, M.D., John T. Brooks, M.D., Debra Birnkrant, M.D., and Peter Kim, M.D.

It stated: that there is a drug tecovirimat (TPOXX), available for clinical use under an expanded-access protocol that might conceivably speed the resolution of monkeypox illness and improve outcomes.

Yet it poses the conundrum: how to manage compassionate access to a drug whose safety and efficacy in humans have not been established.

Tecovirimat was approved for the treatment of smallpox disease under a regulation known as the "Animal Rule."

This U.S. FDA pathway allows for approval of drugs for serious or life-threatening conditions when it is not ethical to conduct efficacy studies in humans.

Since smallpox and monkeypox are caused by the same genus of viruses, to understand better the role that tecovirimat might play in our response to the monkeypox outbreak, it is essential to understand the basis for its approval by the FDA for the treatment of smallpox and the knowledge gaps that remain.

These doctors added: Before the onset of the current outbreak, the National Institutes of Health (NIH) had initiated planning for a randomized, controlled trial (RCT) in the Democratic Republic of Congo (DRC) to evaluate the safety and efficacy of tecovirimat in treating monkeypox.

However, the current worldwide outbreak involves a different clade of monkeypox virus than that which generally causes monkeypox infection in the DRC, and some of the clinical manifestations of the current outbreak and affected populations at this time differ from those in countries where monkeypox is endemic.

Therefore, the NIH is now also developing a U.S.-based RCT to assess the safety and efficacy of tecovirimat for the treatment of monkeypox disease.

The AIDS Clinical Trials Group will conduct this trial. 

We anticipate that these trials will provide data needed for clinical and regulatory decision-making in the USA, concluded this NEJM Perspective.

Additional monkeypox treatment news is posted at

Note: This information was manually curated for mobile readers.

Aug 4, 2022 • 1:11 pm CDT
by Gerd Altmann

Massachusetts-based Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, recently reported financial results and provided business updates for the second quarter of the fiscal year 2022.

In addition to the impressive financial results announced on August 3, 2022, Moderna disclosed its progress in developing mRNA vaccines for other diseases.

Moderna's non-COVID-19 vaccine candidates included, but are not limited to, the following candidates:

  • Phase 3 safety and immunogenicity trial started in June in the Southern Hemisphere for seasonal flu vaccine candidate (mRNA-1010) to support potential accelerated approval. In addition, the company is preparing for a Phase 3 efficacy study in fall 2022 (if needed); Flu (mRNA-1020/-30) Phase 1/2 trial fully enrolled.
  • Combination COVID + flu (mRNA-1073) Phase 1/2 fully enrolled; combination COVID + flu + RSV (mRNA-1230) in preclinical studies, expected to start Phase 1 trial later this year; endemic human coronavirus (mRNA-1287) in preclinical
  • Pediatric hMPV + PIV3 (mRNA-1653) Phase 1b fully enrolled; pediatric RSV + hMPV (mRNA-1365) in preclinical
  • Older adults RSV Phase 3 (mRNA-1345), known as ConquerRSV, is ongoing; pediatric RSV in Phase 1
  • CMV vaccine (mRNA-1647) pivotal Phase 3 study, known as CMVictory, is ongoing
  • EBV vaccine (to prevent infectious mononucleosis) (mRNA-1189) Phase 1 is ongoing; EBV vaccine (to prevent EBV sequelae) (mRNA-1195) in preclinical studies
  • HIV vaccines (mRNA-1644 and mRNA-1574) Phase 1 trials are ongoing
  • HSV vaccine (mRNA-1608) and VZV vaccine (mRNA-1468) in preclinical studies
  • Zika vaccine (mRNA-1893) is ongoing in a Phase 2 study
  • Nipah vaccine (mRNA-1215) Phase 1 study, led by the U.S. NIH, is ongoing (the first participant dosed in July).

Stéphane Bancel, Moderna's CEO, stated in a press release, "Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet with $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing."

"We will continue to invest and grow as we have never been as optimistic about Moderna's future."

"Right now, we have four infectious disease vaccines in Phase 3 trials, and later this year, we expect important data from proof-of-concept studies in rare diseases and immuno-oncology."

"Our teams are actively working to prepare these new product launches to help patients and drive growth."

"This is an exciting time for Moderna as we continue to see significant scientific and business momentum."

Note: Moderna's press release was manually curated for mobile readers.

Aug 4, 2022 • 12:44 pm CDT
by Ann Ca

California-based Vaxcyte, Inc. today announced that the U.S. FDA granted Fast Track designation to VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in adults ages 18 and older.

IPD causes many clinical syndromes, depending on the site of infection (e.g., bacteremia, meningitis.), says the U.S. CDC.

The Company also completed a successful pre-Investigational New Drug meeting with the FDA regarding the VAX-24 pediatric program.

Vaxcyte received positive written feedback from the FDA supporting the initiation of a pediatric study that proceeds directly into infants, contingent on satisfactory topline safety, tolerability, and immunogenicity results from the ongoing VAX-24 Phase 1/2 clinical proof-of-concept study in adults 18 to 64 years of age.

This approach provides the Company with an accelerated clinical path to deliver a potentially best-in-class PCV, VAX-24, to the pediatric population, representing the most significant portion of the pneumococcal vaccine market in the USA.

“Despite high vaccination rates, a broader spectrum PCV remains an important public health need, especially in vulnerable populations such as infants and older adults, due to substantial disease driven by emerging serotypes not covered by currently available vaccines,” said Jim Wassil, EVP, and COO of Vaxcyte, in a press release on August 4, 2022.

Vaxcyte aims to efficiently create and deliver high-fidelity, broad-spectrum vaccines, such as VAX-24, by using modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform.

Vaxcyte is deploying this approach with VAX-24 to add more pneumococcal strains without compromising the overall immune response.

The Fast Track designation is an FDA process designed to facilitate the development and expedite the review of drugs, including vaccines, that treat or prevent serious conditions and fill an unmet medical need.

Additional pneumococcal vaccine news is posted at

Note: This announcement was manually curated for mobile readership.

Aug 4, 2022 • 11:58 am CDT
by Laureetta Williams

FAIR Health recently announced its third study focused on Lyme disease's notable growth in the USA over the past 15 years, and, as a result, it has become an illness of increasing national concern. 

The new Fair Health infographic published on August 2, 2022, reveals vital differences in the prevalence of Lyme disease when comparing rural and urban areas.

From 2016 to 2021, claim lines with Lyme disease diagnoses increased 60% in rural areas and 19% in urban areas, with diagnoses peaking nationally in June and July annually. 

During these summer months, rural areas, on average, had a more significant share of claim lines associated with Lyme disease diagnoses than urban areas.

However, Lyme disease diagnoses occurred more often in urban areas from November to April.

The top states in 2021, from highest to lowest, were New Jersey, Vermont, Maine, Rhode Island, and Connecticut.

Maine, which was not previously on the list of top five states for Lyme disease claim lines, assumed third place in 2021, suggesting a growing presence of tick-borne illness in the state.

Connecticut and Vermont switched places, with Vermont emerging as number two and Connecticut dropping to number five.

In a press release, FAIR Health President Robin Gelburd stated, "Lyme disease remains a growing public health concern."

"FAIR Health will continue to use its repository of claims data to provide actionable and relevant insights to healthcare stakeholders seeking to better understand the ongoing rise of Lyme disease cases."

While the U.S. FDA has not approved a Lyme disease vaccine as of August 4, 2022, one vaccine candidate is conducting a late-stage study on Nantucket and Block Islands this summer.

Valneva SE Lyme Disease vaccine candidate VLA15 is a multivalent recombinant protein vaccine targeting the outer surface protein A of Borrelia, designed for prophylactic, active immunization against Lyme disease. 

Valneva recently partnered with Pfizer Inc. to bring this vaccine to market in the USA.

Note: This information was manually curated for mobile readership.

Aug 2, 2022 • 2:26 pm CDT
from Pixabay

The U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response (ASPR) today announced its expanded allocations of U.S. FDA-authorized COVID-19 therapeutics, oral antiviral, and monoclonal antibodies (mAbs).

Since December 2021, ASPR has distributed about 9,975,306 COVID-19 therapeutics. 

On August 1, 2022, ASPR confirmed state and territorial health departments would receive 938,108 products this week:

Oral antivirals: Paxlovid (612,260) and Lagevrio (92,328).

mAbs: Evusheld (203,760) and Bebtelovimab (29,760).

At the state level, California will receive the largest allocation (42,035), followed by Texas, Florida, and New York.

ASPR says: 'State and territorial health department officials can request additional products at any time if a jurisdiction's current supply is insufficient to meet demand.'

To expand access, the U.S. government launched the 'Test to Treat' initiative in March 2022.

Through this program, people can get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a healthcare provider (either on-site or through telehealth) and have their prescription filled all at one location.

These "One-Stop Test to Treat" sites are available at locations nationwide, including pharmacy-based clinics.

Note: The ASPR information was manually curated for mobile readership.

Aug 2, 2022 • 6:58 am CDT
U.S. White House

The U.S. President appointed today officials from the Federal Emergency Management Agency (FEMA) and the U.S. Centers for Disease Control and Prevention (CDC) to coordinate the administration's response to the monkeypox outbreak in the United States.

On August 2, 2022, Robert Fenton, Region #9 Administrator at FEMA, was identified as the White House Coordinator, and Demetre Daskalakis, M.D., current director of CDC's HIV prevention division, was named the Deputy Coordinator.

"Bob Fenton and Dr. Daskalakis are proven, effective leaders that will lead a whole of government effort to implement President Biden's comprehensive monkeypox response strategy with the urgency that this outbreak warrants," said Anthony Fauci, Chief Medical Advisor to the President, in a media statement.

As of August 1, 2022, the CDC had reported 5,811 monkeypox/orthopoxvirus cases since the initial case was confirmed in Massachusetts in May 2022.

Currently, the USA leads all other countries in reporting cases.

And data sources indicate the global monkeypox outbreak has reached over 80 countries and about 24,958 individuals as of August 2, 2022.

The U.S. government has been distributing the non-replicating monkeypox vaccine Jynneos® produced by Bavarian Nordic, which the U.S. FDA licensed in September 24, 2019.

As of July 2​​7, 2022, the U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response had delivered 336,710 ​doses of Jynneos to certain states.

To clarify the use of Jynneos, the CDC recently published Considerations for Monkeypox Vaccination.

The CDC says the immune response is maximized after 14 days from the second dose of Jynneos. Therefore, people who get vaccinated should continue to take steps to protect themselves from infection.

However, the CDC confirmed in July, 'There is minimal evidence on whether Jynneos can modify disease following exposure to this version of the monkeypox virus.'

Additional monkeypox vaccine news is posted at

Note: The information was curated for mobile readership.

Aug 1, 2022 • 2:00 pm CDT
by Tim Okefoto

A peer-reviewed study recently published in the American Journal of Infection Control found that 10% of infections caused by carbapenem-resistant Enterobacterales (CRE) were community-associated, occurring in patients without known healthcare risks such as hospitalization or in long-term care facilities.

The 10% of cases that were California-CRE is near the upper boundary of the 5.6%-10.8% range identified among the four studies conducted in the USA.

Furthermore, molecular analysis of samples from those infections identified the presence of an enzyme that makes bacteria resistant to multiple classes of antibiotics and is carried on mobile genetic elements that are easily shared with other bacteria.

These findings, published on July 27, 2022, suggest the importance of case investigations of United States CA-CP-CRE that include patient interviews to characterize risk factors that might not be well-documented in the medical record and to inform prevention efforts for CP-CRE transmission.

Moreover, this study's findings are concerning because CRE infections are resistant to most antibiotics and are considered a significant public health threat by the U.S. CDC

More than 2.8 million antimicrobial-resistant infections occur in the USA each year, and more than 35,000 people die as a result.

In November 2021, the CDC listed the germs in three categories—urgent, serious, and concerning—based on human health concerns.

The CDC's report also includes a Watch List with three threats that have not spread widely in the U.S. but could become common without continued aggressive action.

As of August 1, 2022, no preventive vaccines are authorized to target CRE.

Note: This study's summary was manually curated for mobile readers.

Aug 1, 2022 • 1:29 pm CDT
by Thorsten Frenzel

Switzerland-based ACM Biolabs recently announced that the first subject had been dosed in the first–in–human Phase 1 clinical trial of its candidate vaccine, ACM-001, a 2nd generation adjuvanted SARS-CoV-2 spike protein vaccine with broad protection against variants of concerns.

"Our next generation COVID-19 vaccine ACM-001, a nasal vaccine, can make a significant contribution to blocking infections and transmission. The current situation of high infection and reinfection rates despite repeated booster vaccinations reinforces the emerging consensus of the scientific community that there is a high need for an intranasal COVID vaccine," said Dr. Madhavan Nallani, CEO of ACM Biolabs, in a press release on July 29, 2022.

"We look forward to seeing our promising preclinical results translate into this important Phase 1 study within the next months."

The spike-protein component of ACM-001 is modeled after the immune-evasive beta variant.

In animal studies, the clinical vaccine candidate was safe and generated a protective immune response against the beta-variant and ancestral form of SARS-2.

Additionally, it also elicited broadly neutralizing antibodies against other variants, including delta and omicron.

Furthermore, the plug-and-play platform would allow for quick adaption of current and future mutations of the SARS-2 virus.

ACM-001 vaccine is developed based on the company's proprietary artificial cell membrane (ACM) polymer-based technology.

This next-generation delivery platform offers flexibility with multiple payloads (proteins to RNA) and can be stored in a refrigerator, in contrast to the current LNP-based delivery.

ACM Biolabs is a biotechnology company operating in Singapore, Switzerland, and Australia. It focuses on developing vaccines for infectious diseases and personalized immunotherapy for cancer patients using its proprietary delivery platform (non-lipid, non-viral).

Note: The company's press statement was translated and curated for mobile readers.

Jul 31, 2022 • 4:24 am CDT
Image by Firmbee

The American Medical Association (AMA) recently announced an update to Current Procedural Terminology (CPT)® that includes a new laboratory test code for the orthopoxvirus and two codes for the vaccines utilized to prevent monkeypox infection.

These new CPT codes are important to ensure people are charged, or not, for these services in the USA.

The new laboratory test CPT code (87593) describes molecular diagnostic testing that detects the nucleic signature of an orthopoxvirus, including the monkeypox virus.

And the two new vaccine codes are designed to describe the two smallpox and monkeypox virus products currently available.

The first code (90622) describes the existing FDA-approved ACAM2000 vaccine manufactured by Sanofi Pastuer Biologics Co. for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.

The second code (90611) describes the FDA-approved JYNNEOS vaccine manufactured by Bavarian Nordic to prevent smallpox and monkeypox disease in adults 18 years of age and older at high risk for smallpox or monkeypox infection.

"In the wake of the WHO declaring monkeypox a global health emergency, and with case numbers increasing in the United States, these CPT updates are timely," said AMA President Jack Resneck Jr., M.D., in a press release on July 26, 2022.

"The daily increase in cases in the USA shows community spread occurring."

"However, we are relieved to see access to testing has increased to 80,000 specimens per week with commercial labs now online, and vaccine supply is increasing."

"Monkeypox is most often spread from person to person through close personal contact, but preventive measures can help you avoid infection."

"We urge patients to check trusted, evidence-based sources like the CDC and AMA and to contact their physician if they have questions about prevention, diagnosis, or treatment of monkeypox."

Note: This AMA press release was manually curated for mobile readers.

Jul 31, 2022 • 4:07 am CDT

The U.S. CDC Health Alert Network (HAN) issued an Offical Health Update (CDCHAN-00472) regarding the expanding monkeypox virus outbreak in the USA,

Published on July 30, 2022, this HAN update alerts clinicians to clinical considerations for preventing, diagnosing, and managing monkeypox in people with HIV, children, adolescents, and pregnant or breastfeeding women.

These newly released clinical considerations complement existing guidance for managing monkeypox and provide information on the signs and symptoms of Monkeypox virus (MPXV) infection, pre-and post-exposure prevention, treatment, and infection control in these populations.

The CDC says 'clinicians should be familiar with unique clinical considerations for monkeypox in these patient populations.'

'A broad diagnostic approach is encouraged to distinguish MPXV infection from other causes of fever and rash illness.'

'Testing should be performed on persons for whom monkeypox is suspected based on clinical presentation or epidemiologic criteria.'

Moreover, the CDC encourages vaccinations with the U.S. FDA-approved Jynneos vaccine for specific individuals.

In the USA, there have been 5,189 MPXV infections across 47 states, Washington, D.C., and Puerto Rico, since early May 2022. This data includes two children who have been diagnosed with MPXV.

Furthermore, New York and San Francisco announced emergency status on July 28, 2022. 

And globally, data sources indicate about 22,870 MPXV cases and (3) related fatalities have been reported as of July 31, 2022.

Monkeypox vaccines news is posted at

Note: This CDC HAN was curated for mobile readership. Interested readers should view the entire HAN.

Jul 31, 2022 • 3:42 am CDT
Image from Pixabay

England-based ViiV Healthcare and the Medicines Patent Pool (MPP) recently announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).

Through this agreement, selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP, the first long-acting HIV prevention medicine in 90 countries.

This announcement comes just seven months after the first regulatory approval of cabotegravir LA by the U.S. FDA for at-risk adults and adolescents weighing at least 35kg to reduce the risk of sexually acquired HIV-1 infection.

 Cabotegravir LA for PrEP (Apretude) is a long-acting injectable that has recently gained its first regulatory approval for HIV prevention in the USA.

Deborah Waterhouse, CEO at ViiV Healthcare, said in a press release on July 28, 2022, "This announcement represents a potentially game-changing moment in HIV prevention."

"Enabling at-scale access to generic cabotegravir LA for PrEP could play a significant role in averting the transmission of HIV, particularly amongst women and adolescent girls, and help end the HIV epidemic."

Each year, there are approximately 1.5 million new cases of HIV worldwide, most of which occur in resource-limited countries, with women and adolescent girls disproportionately impacted.

While oral PrEP options are available in many countries, challenges with adherence and stigma have limited their impact on some populations.

Access to an effective long-acting HIV prevention option could significantly contribute toward the goal of ending the epidemic.

ViiV Healthcare and MPP will now work closely with stakeholders and generic manufacturers to enable access to generic cabotegravir LA for PrEP as soon as possible.

Note: This medicine is not a U.S. FDA-approved vaccine. HIV vaccine candidate news is posted at

Jul 30, 2022 • 12:56 pm CDT

When the State of New York recently confirmed an unvaccinated resident was diagnosed with polio, it was the first case of polio in the U.S. since 2013.

Announced on July 21, 2022, the Rockland County, NY, patient reportedly contracted a form of polio that can be traced back to the live, but weakened, poliovirus used in the oral polio vaccine (OPV).

NY health officials said the version of poliovirus affecting the male patient, who has muscle weakness and paralysis, likely originated somewhere overseas, where oral vaccines are still administered.

Following the NY detection, the Global Polio Laboratory Network confirmed on July 29, 2022, that the VDPV2 isolated was genetically linked to two Sabin-like type 2 isolates, related to environmental samples collected in New York, Israel, and London, UK, during June 2022.

This polio vaccine version has not been used in the U.S. since 2000.

With more than 10 billion doses of the OPV administered since 2000, there have been about 800 cases of vaccine-derived polio reported.

The eradication of polio in the Americas has been accomplished solely through the use of the live oral vaccine. 

The U.S. CDC has endorsed the inactivated polio vaccine (IPV), which offers nearly complete protection from paralytic polio.

Most children receive the IPV at 2, 4, and 6 months of age.

William Petri, the chair of the WHO's Polio Research Committee, explained to The Conversation on July 22, 2022, what vaccine-derived poliovirus is and why the IPV vaccine can't cause it.

The weakened form of the live virus in the oral vaccine cannot cause disease.

However, because the vaccine is given orally, the weakened virus is excreted in the feces and can spread from someone vaccinated.

If the weakened virus circulates person to person for long enough, it can mutate and regain its ability to cause paralysis.

The mutated virus can then infect people in communities with poor sanitation and low vaccination rates, causing disease and even paralysis.

This is an exceedingly rare occurrence.

However, as a precaution, Israel vaccinated about five million children in April 2022.

The good news is a safer oral polio vaccine engineered not to mutate is now replacing the earlier live-virus vaccine in targeted countries.

Approximately 370 million doses of nOPV2 have been administered across 21 countries under its WHO Emergency Use Listing to date. 

To alert international travelers of their polio risks, the CDC stated on July 27, 2022, 'before any international travel to Africa, Asia, or Eastern Europe, anyone unvaccinated, incompletely vaccinated, or with an unknown polio vaccination status should complete the routine polio vaccine series.'

Other polio vaccination news is posted at

Note: This article is republished from The Conversation under a Creative Commons license. And was manually curated for mobile readership.